Related Experiment Video
Updated: May 2, 2026

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens
Katharine M Ng1, Jessica A Ferreyra, Steven K Higginbottom
1Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Abstract:
The human intestine, colonized by a dense community of resident microbes, is a frequent target of bacterial pathogens. Undisturbed, this intestinal microbiota provides protection from bacterial infections. Conversely, disruption of the microbiota with oral antibiotics often precedes the emergence of several enteric pathogens. How pathogens capitalize upon the failure of microbiota-afforded protection is largely unknown. Here we show that two antibiotic-associated pathogens, Salmonella enterica serovar Typhimurium (S. typhimurium) and Clostridium difficile, use a common strategy of catabolizing microbiota-liberated mucosal carbohydrates during their expansion within the gut. S. typhimurium accesses fucose and sialic acid within the lumen of the gut in a microbiota-dependent manner, and genetic ablation of the respective catabolic pathways reduces its competitiveness in vivo. Similarly, C. difficile expansion is aided by microbiota-induced elevation of sialic acid levels in vivo. Colonization of gnotobiotic mice with a sialidase-deficient mutant of Bacteroides thetaiotaomicron, a model gut symbiont, reduces free sialic acid levels resulting in C. difficile downregulating its sialic acid catabolic pathway and exhibiting impaired expansion. These effects are reversed by exogenous dietary administration of free sialic acid. Furthermore, antibiotic treatment of conventional mice induces a spike in free sialic acid and mutants of both Salmonella and C. difficile that are unable to catabolize sialic acid exhibit impaired expansion. These data show that antibiotic-induced disruption of the resident microbiota and subsequent alteration in mucosal carbohydrate availability are exploited by these two distantly related enteric pathogens in a similar manner. This insight suggests new therapeutic approaches for preventing diseases caused by antibiotic-associated pathogens.
Insights
Antibiotic use disrupts gut microbiota, allowing pathogens like Salmonella and Clostridium difficile to thrive by consuming released sugars. Targeting this sugar metabolism offers new therapeutic strategies against gut infections.
Area of Science:
- Microbiology
- Gastroenterology
- Infectious Diseases
Background:
- The human gut microbiota protects against bacterial pathogens.
- Antibiotic disruption of the microbiota can lead to enteric pathogen emergence.
- Mechanisms by which pathogens exploit microbiota disruption are poorly understood.
Purpose of the Study:
- To investigate how enteric pathogens Salmonella enterica serovar Typhimurium (S. typhimurium) and Clostridium difficile capitalize on antibiotic-induced microbiota failure.
- To identify common strategies used by these pathogens to expand within the gut.
Main Methods:
- Studied S. typhimurium and C. difficile in gnotobiotic and conventional mice.
- Utilized genetic mutants deficient in carbohydrate catabolism pathways.
- Administered antibiotics and exogenous sialic acid to assess pathogen expansion.
- Measured mucosal carbohydrate availability and pathogen gene expression.
Main Results:
- Both S. typhimurium and C. difficile utilize microbiota-liberated mucosal carbohydrates (fucose, sialic acid) for gut expansion.
- Genetic disruption of these catabolic pathways impairs pathogen competitiveness.
- Antibiotic treatment increases free sialic acid, benefiting C. difficile and S. typhimurium.
- Sialidase-deficient bacteria reduce free sialic acid, hindering C. difficile expansion.
Conclusions:
- Enteric pathogens exploit antibiotic-induced changes in gut carbohydrate availability.
- Catabolism of mucosal carbohydrates is a shared strategy for pathogen expansion.
- Targeting pathogen carbohydrate metabolism presents a potential therapeutic avenue against antibiotic-associated gut infections.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Probiotics
The Oral Microbiota
Microbiota of the Stomach and Small Intestine
Microbiota of the Large Intestine
Functions of the Gut Microbiota

